目的 汇总同煤集团总医院肿瘤内科铂类抗肿瘤药物的使用情况，对化疗过程中可能出现的不良反应进行分析，促进临床合理、安全用药。方法 收集2016年10月—2017年10月同煤集团总医院肿瘤内科所有铂类药物不良反应的报告，并对药物基本使用情况与患者用药信息进行记录和分析。结果 共有943例患者使用铂类药物，发生不良反应458例，不良反应发生率为48.57%。铂类药物不良反应在中年女性中发生率较高，肺癌患者最多，占35.59%。不良反应主要表现为血液系统毒性、胃肠道毒性、神经系统毒性。98.03%患者不良反应预后良好。结论 临床药师应当密切关注铂类化疗药物的不良反应，预防不良反应的发生，降低不良反应的发生率，保障肿瘤患者用药安全。

Objective To summarize the usage situation of platinum anti-tumor drugs in Department of Medical Oncology in General Hospital of Datong Coal Group, and to analyze the possible adverse reactions in the course of chemotherapy, and to promote the rational and safety medication in clinic. Methods The reports of adverse reactions of induced by platinum drugs in Department of Medical Oncology General Hospital of Datong Coal Group from October 2016 to October 2017 were collected, and the basic usage situation of drugs and the patient's medication information were recorded and analyzed. Results Patients (943 cases) used platinum drugs, while there were 458 cases of adverse reactions, and the rate was 48.57%. Middle-aged women had higher incidence of adverse reactions. And more were patients with lung cancer, and the incidence of adverse reactions was 35.59%. The main performances of adverse reactions were blood system toxicity, gastrointestinal system toxicity, and nerve system toxicity. The prognosis of 98.03% patients was favorable. Conclusion Clinical pharmacists should pay close attention to the adverse reactions of platinum chemotherapy drugs, prevent the occurrence of adverse reactions, reduce the incidence of adverse reactions, and ensure the safety medication in cancer patients.